



Legislation Details (With Text)

File #:	22-2011	Version:	1	Name:	
Type:	CONSENT AGENDA		Status:	Approved	
File created:	9/2/2022		In control:	Office of Community Care	
On agenda:	9/28/2022		Final action:		
Title:	Authorize the acceptance of the Interlocal Agreement between the City of Dallas and the Dallas County to allow (1) for the use of the facilities at the West Dallas Multipurpose Center, a facility of the City of Dallas, to provide the community with vaccinations for the monkeypox; and (2) to provide for the execution of the agreement and all terms, conditions and documents required by the agreement, for a period of October 1, 2022 through September 30, 2023, including mutual indemnity, waiver of jury trial, and venue - Financing: No cost consideration to the City				
Sponsors:					
Indexes:	100				
Code sections:					
Attachments:	1. Resolution				

Date	Ver.	Action By	Action	Result
------	------	-----------	--------	--------

STRATEGIC PRIORITY:	Workforce, Education, & Equity
AGENDA DATE:	September 28, 2022
COUNCIL DISTRICT(S):	All
DEPARTMENT:	Office of Community Care
EXECUTIVE:	M. Elizabeth Cedillo-Pereira

SUBJECT

Authorize the acceptance of the Interlocal Agreement between the City of Dallas and the Dallas County to allow **(1)** for the use of the facilities at the West Dallas Multipurpose Center, a facility of the City of Dallas, to provide the community with vaccinations for the monkeypox; and **(2)** to provide for the execution of the agreement and all terms, conditions and documents required by the agreement, for a period of October 1, 2022 through September 30, 2023, including mutual indemnity, waiver of jury trial, and venue - Financing: No cost consideration to the City

BACKGROUND

Monkeypox is an orthopoxvirus that is related to the smallpox virus. It has been associated with sporadic outbreaks over the past decades. Since May 2022, an outbreak of monkeypox has been ongoing in several countries, including the United States. JYNNEOS is the only vaccine that is FDA-approved for the prevention of monkeypox disease. JYNNEOS is approved for use in individuals 18 years of age and older who are determined to be at high risk for smallpox or monkeypox infection.

JYNNEOS is approved for administration as a two-dose series, 4 weeks apart.

On August 9, 2022, FDA issued an emergency use authorization (EUA) for JYNNEOS to allow healthcare providers to administer the vaccine for individuals 18 years of age and older who are determined to be at high risk for monkeypox infection.

PRIOR ACTION/REVIEW (COUNCIL, BOARDS, COMMISSIONS)

This item has no prior action.

FISCAL INFORMATION

No cost consideration to the City.